ロード中...
The concomitant use of lapatinib and paracetamol - the risk of interaction
Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of drug interactions during therapy. The aim of the study was t...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6153549/ https://ncbi.nlm.nih.gov/pubmed/29464465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0573-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|